| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
126,890,000 |
| Market
Cap: |
1.15(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.07 - $9.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
9,840,628 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,171,858 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
25 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bianco James A |
President and CEO |
• • – |
2007-01-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(200,000) |
456,486 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2006-12-29 |
5 |
GD |
$0.00 |
$0 |
D/D |
48,333 |
656,486 |
|
- |
|
| Stromatt Scott |
EVP, Clinical Dev & Reg Affair |
• – – |
2006-12-22 |
4 |
AS |
$1.81 |
$36,200 |
D/D |
(20,000) |
25,000 |
|
- |
|
| Singer Jack W |
EVP, Chief Medical Officer |
• • – |
2006-12-14 |
4 |
S |
$1.86 |
$4,883 |
D/D |
(2,625) |
439,465 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2006-12-14 |
4 |
S |
$1.80 |
$68,170 |
D/D |
(37,893) |
704,819 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2006-12-14 |
4 |
AS |
$1.86 |
$13,950 |
D/D |
(7,500) |
198,564 |
|
- |
|
| Singer Jack W |
EVP, Chief Medical Officer |
• • – |
2006-12-13 |
4 |
S |
$1.89 |
$25,326 |
D/D |
(13,400) |
442,090 |
|
- |
|
| Stromatt Scott |
EVP, Clinical Dev & Reg Affair |
• – – |
2006-12-13 |
4 |
S |
$1.89 |
$14,181 |
D/D |
(7,500) |
45,000 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2006-12-13 |
4 |
AS |
$1.89 |
$24,568 |
D/D |
(12,999) |
206,064 |
|
- |
|
| Bianco Louis A |
EVP, Finance & Administration |
• – – |
2006-12-11 |
4 |
AS |
$1.92 |
$16,641 |
D/D |
(8,667) |
219,063 |
|
- |
|
| Singer Jack W |
EVP, Chief Medical Officer |
• • – |
2006-12-11 |
4 |
AS |
$1.92 |
$3,072 |
D/D |
(1,600) |
455,490 |
|
- |
|
| Gregorian Vartan |
Director |
– • – |
2006-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
10,000 |
|
- |
|
| Telling Fred |
Director |
– • – |
2006-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Brown Jade |
EVP, Chief Business Officer |
• – – |
2006-10-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(57,329) |
10,667 |
|
- |
|
| Bauer John H |
Director |
– • – |
2006-10-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
5,000 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2006-09-29 |
4 |
S |
$1.71 |
$64,325 |
D/D |
(37,500) |
742,712 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2006-09-18 |
4 |
AS |
$2.03 |
$80,348 |
D/D |
(37,500) |
780,212 |
|
- |
|
| Stromatt Scott |
EVP, Clinical Dev & Reg Affair |
• – – |
2006-08-30 |
4 |
AS |
$1.54 |
$3,850 |
D/D |
(2,500) |
52,500 |
|
- |
|
| Brown Jade |
EVP, Chief Business Officer |
• – – |
2006-06-23 |
4 |
AS |
$1.38 |
$13,406 |
D/D |
(9,500) |
67,996 |
|
- |
|
| Eramian Daniel G |
EVP, Corporate Communications |
• – – |
2006-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
55,000 |
|
- |
|
| Brown Jade |
EVP, Chief Business Officer |
• – – |
2006-06-21 |
4 |
AS |
$1.42 |
$18,136 |
D/D |
(12,500) |
77,496 |
|
- |
|
| Stromatt Scott |
EVP, Clinical Dev & Reg Affair |
• – – |
2006-06-20 |
4 |
AS |
$1.39 |
$27,900 |
D/D |
(20,000) |
55,000 |
|
- |
|
| Bianco James A |
President and CEO |
• • – |
2006-05-08 |
4 |
S |
$1.77 |
$115,180 |
D/D |
(65,000) |
817,712 |
|
- |
|
| Nudelman Phillip M Phd |
Director |
– • – |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
52,405 |
|
- |
|
| Mundinger Mary Oneil |
Director |
– • – |
2006-04-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
4,150 |
|
- |
|
742 Records found
|
|
Page 26 of 30 |
|
|
